copper radioisotopes

Summary

Summary: Unstable isotopes of copper that decay or disintegrate emitting radiation. Cu atoms with atomic weights 58-62, 64, and 66-68 are radioactive copper isotopes.

Top Publications

  1. Blower P, Lewis J, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol. 1996;23:957-80 pubmed
    ..The chemistry of copper, of which only a fraction has yet been exploited, is likely to be applied more fully in the future. ..
  2. Matsumoto K, Fujibayashi Y, Konishi J, Yokoyama A. [Radiolabeling and biodistribution of 62Cu-dithiocarbamate--an application for the new 62Zn/62Cu generator]. Radioisotopes. 1990;39:482-6 pubmed
    ..Further studies with Cu-dithiocarbamic acid derivatives for development of new generator-produced 62Cu positron radiopharmaceuticals can be recalled...
  3. Lears K, Ferdani R, Liang K, Zheleznyak A, Andrews R, Sherman C, et al. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer. J Nucl Med. 2011;52:470-7 pubmed publisher
  4. Dehdashti F, Mintun M, Lewis J, Bradley J, Govindan R, Laforest R, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30:844-50 pubmed
    ..04; P=0.9). (60)Cu-ATSM-PET can be readily performed in patients with NSCLC and the tumor uptake of (60)Cu-ATSM reveals clinically unique information about tumor oxygenation that is predictive of tumor response to therapy. ..
  5. Dehdashti F, Grigsby P, Lewis J, Laforest R, Siegel B, Welch M. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med. 2008;49:201-5 pubmed publisher
    ..9). Pretherapy (60)Cu-ATSM PET provides clinically relevant information about tumor oxygenation that is predictive of outcome in patients with cervical cancer...
  6. Ait Mohand S, Fournier P, Dumulon Perreault V, Kiefer G, Jurek P, Ferreira C, et al. Evaluation of 64Cu-labeled bifunctional chelate-bombesin conjugates. Bioconjug Chem. 2011;22:1729-35 pubmed publisher
    ..Our data also show that (64)Cu-labeled NOTA- and PCTA-BBN peptide conjugates are promising radiotracers for PET imaging of many human cancers overexpressing the GRP receptor...
  7. Dence C, Ponde D, Welch M, Lewis J. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer. Nucl Med Biol. 2008;35:713-20 pubmed publisher
  8. Seo J, Zhang H, Kukis D, Meares C, Ferrara K. A novel method to label preformed liposomes with 64Cu for positron emission tomography (PET) imaging. Bioconjug Chem. 2008;19:2577-84 pubmed publisher
    ..Our results suggest that this fast and easy 64Cu labeling of liposomes could be exploited in tracking liposomes in vivo for medical imaging and targeted delivery...
  9. Xie J, Chen K, Huang J, Lee S, Wang J, Gao J, et al. PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials. 2010;31:3016-22 pubmed publisher

More Information

Publications66

  1. Wood K, Wong W, Saunders M. [(64)Cu]diacetyl-bis(N(4)-methyl-thiosemicarbazone) - a radiotracer for tumor hypoxia. Nucl Med Biol. 2008;35:393-400 pubmed publisher
    ..It outlines the potential use of this radiotracer for imaging in the field of oncology...
  2. Ferreira C, Yapp D, Lamsa E, Gleave M, Bensimon C, Jurek P, et al. Evaluation of novel bifunctional chelates for the development of Cu-64-based radiopharmaceuticals. Nucl Med Biol. 2008;35:875-82 pubmed publisher
    ..3.1]pentadeca-1(15),11,13-triene-S-4-(4-nitrobenzyl)-3,6,9-triacetic acid (p-NO(2)-Bn-PCTA), with the commonly used S-2-(4-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (p-NO(2)-Bn-DOTA)...
  3. Wadas T, Anderson C. Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64. Nat Protoc. 2006;1:3062-8 pubmed
    ..In both cases, the conjugates can be radiolabeled with 64Cu at greater than 95% purity and with specific activities of 37-111 MBq microg(-1) (1-3 mCi microg(-1)). Both protocols are straightforward and can be completed within 3 h...
  4. Wadas T, Wong E, Weisman G, Anderson C. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr Pharm Des. 2007;13:3-16 pubmed
    ..This review discusses the necessary characteristics of an effective (64)Cu chelator, while highlighting the development and evaluation of (64)Cu-complexes attached to biologically-targeted ligands...
  5. Williams H, Robinson S, Julyan P, Zweit J, Hastings D. A comparison of PET imaging characteristics of various copper radioisotopes. Eur J Nucl Med Mol Imaging. 2005;32:1473-80 pubmed
    ..examines the radioisotope characteristics, imaging performance, radiation dosimetry and production modes of the four copper radioisotopes, ( 60)Cu,( 61)Cu,( 62)Cu and( 64)Cu, to assess their merits for different PET imaging applications.
  6. Nimmagadda S, Pullambhatla M, Stone K, Green G, Bhujwalla Z, Pomper M. Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography. Cancer Res. 2010;70:3935-44 pubmed publisher
    ..Our findings show the feasibility of imaging CXCR4 by positron emission tomography using a clinically approved agent as a molecular scaffold. ..
  7. Ikotun O, Lapi S. The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86. Future Med Chem. 2011;3:599-621 pubmed publisher
    ..This review focuses on the biological probes and processes that have been examined, in additiom to the preclinical and clinical findings with nonstandard radiometals: copper-64, zirconium-89, and yttrium-86...
  8. Ikawa M, Okazawa H, Kudo T, Kuriyama M, Fujibayashi Y, Yoneda M. Evaluation of striatal oxidative stress in patients with Parkinson's disease using [62Cu]ATSM PET. Nucl Med Biol. 2011;38:945-51 pubmed publisher
  9. Shokeen M, Anderson C. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc Chem Res. 2009;42:832-41 pubmed publisher
  10. Elsässer Beile U, Reischl G, Wiehr S, Bühler P, Wolf P, Alt K, et al. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med. 2009;50:606-11 pubmed publisher
    ..This article reports the in vivo behavior and tumor uptake of the radiolabeled anti-PSMA mAb 3/A12 and its potential as a tracer for PET...
  11. Prasanphanich A, Retzloff L, Lane S, Nanda P, Sieckman G, Rold T, et al. In vitro and in vivo analysis of [(64)Cu-NO2A-8-Aoc-BBN(7-14)NH(2)]: a site-directed radiopharmaceutical for positron-emission tomography imaging of T-47D human breast cancer tumors. Nucl Med Biol. 2009;36:171-81 pubmed publisher
    ..64)Cu-NO2A-8-Aoc-BBN(7-14)NH(2) (NO2A=1,4,7-triazacyclononane-1,4-diacetate) has produced high-quality microPET images of GRPR-positive breast cancer xenografted tumors in mice...
  12. Xie H, Wang Z, Bao A, Goins B, Phillips W. In vivo PET imaging and biodistribution of radiolabeled gold nanoshells in rats with tumor xenografts. Int J Pharm. 2010;395:324-30 pubmed publisher
    ..Overall, PET images with (64)Cu had good resolution and therefore can be further applied to guide photothermal treatment of cancer...
  13. McCabe K, Wu A. Positive progress in immunoPET--not just a coincidence. Cancer Biother Radiopharm. 2010;25:253-61 pubmed publisher
    ..Antibody-based PET probes constitute a valuable class of molecular imaging agents, and the progress made preclinically should expedite the transition of these targeted diagnostics to clinical applications...
  14. Galibert M, Jin Z, Furukawa T, Fukumura T, Saga T, Fujibayashi Y, et al. RGD-cyclam conjugate: synthesis and potential application for positron emission tomography. Bioorg Med Chem Lett. 2010;20:5422-5 pubmed publisher
    ..These molecules encompass two functional domains, one a tumour 'homing' domain and the other a chelating ligand for copper allowing nuclear imaging of tumours...
  15. Xie H, Diagaradjane P, Deorukhkar A, Goins B, Bao A, Phillips W, et al. Integrin ?v?3-targeted gold nanoshells augment tumor vasculature-specific imaging and therapy. Int J Nanomedicine. 2011;6:259-69 pubmed publisher
    ..Active targeting of NSs to integrin ?v?3 offers the potential to increase accumulation preferentially in tumors and thereby enhance therapy efficacy...
  16. Bayly S, King R, Honess D, Barnard P, Betts H, Holland J, et al. In vitro and in vivo evaluations of a hydrophilic 64Cu-bis(thiosemicarbazonato)-glucose conjugate for hypoxia imaging. J Nucl Med. 2008;49:1862-8 pubmed publisher
    ..Here we report our initial biological experiments with 64Cu-ATSE/A-G and compare the results with those obtained for 64Cu-ATSM and 18F-FDG...
  17. Dumont R, Hildebrandt I, Su H, Haubner R, Reischl G, Czernin J, et al. Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. Cancer Res. 2009;69:3173-9 pubmed publisher
    ..50+/-17.68 mm(2) in controls; P=0.001). [(64)Cu]DOTA-c(RGDfK) may provide a sensitive means of monitoring tumor response to SFK inhibition in alpha(V)beta(3)-expressing cancers early in the course of therapy...
  18. Sun X, Kim J, Martell A, Welch M, Anderson C. In vivo evaluation of copper-64-labeled monooxo-tetraazamacrocyclic ligands. Nucl Med Biol. 2004;31:1051-9 pubmed
    ..However, the data presented here suggest that neutral or negatively charged Cu(II) complexes of tetraazamacrocyclic ligands with a cyclam backbone (tetradecane) are optimal for copper radiopharmaceutical applications...
  19. Liu Z, Li Z, Cao Q, Liu S, Wang F, Chen X. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer. J Nucl Med. 2009;50:1168-77 pubmed publisher
    ..To further investigate the synergistic effect of the dual-receptor targeting of peptide heterodimers, we evaluated (64)Cu-labeled RGD-bombesin for PET imaging of tumors...
  20. Huang C, Li Z, Cai H, Shahinian T, Conti P. Biological stability evaluation of the ?2?1 receptor imaging agents: diamsar and DOTA conjugated DGEA peptide. Bioconjug Chem. 2011;22:256-63 pubmed publisher
    ..Free carboxyl groups may naturally compete with DOTA for (64)Cu(2+) binding and therefore reduce the complex stability...
  21. Minagawa Y, Shizukuishi K, Koike I, Horiuchi C, Watanuki K, Hata M, et al. Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study. Ann Nucl Med. 2011;25:339-45 pubmed publisher
    ..We undertook a pilot study in patients with locally advanced head and neck cancer to determine whether there is a relationship between tumor uptake of (62)Cu-ATSM and response to chemoradiotherapy...
  22. Hong H, Yang Y, Zhang Y, Engle J, Barnhart T, Nickles R, et al. Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging. 2011;38:1335-43 pubmed publisher
    ..The goal of this study was to develop a positron emission tomography (PET) tracer for imaging CD105 expression...
  23. Sun X, Wuest M, Weisman G, Wong E, Reed D, Boswell C, et al. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. J Med Chem. 2002;45:469-77 pubmed
    ..A bifunctional chelator of 2 is a significant candidate for labeling copper radionuclides to biological molecules for diagnostic imaging and targeted radiotherapy...
  24. De Silva R, Peyre K, Pullambhatla M, Fox J, Pomper M, Nimmagadda S. Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465. J Nucl Med. 2011;52:986-93 pubmed publisher
    ..Our results show that (64)Cu-AMD3465 is capable of detecting lesions in a CXCR4-dependent fashion, with high target selectivity, and may offer a scaffold for the synthesis of clinically translatable agents...
  25. Rossin R, Pan D, Qi K, Turner J, Sun X, Wooley K, et al. 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation. J Nucl Med. 2005;46:1210-8 pubmed
    ..The purpose of this study was to evaluate 64Cu-radiolabeled folate-conjugated shell cross-linked nanoparticles (SCKs) as candidate agents to shuttle radionuclides and drugs into tumors overexpressing the folate receptor (FR)...
  26. Niu G, Li Z, Xie J, Le Q, Chen X. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med. 2009;50:1116-23 pubmed publisher
  27. Bowen S, van der Kogel A, Nordsmark M, Bentzen S, Jeraj R. Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling. Nucl Med Biol. 2011;38:771-80 pubmed publisher
    ..Differences in imaged uptake of two common hypoxia radiotracers, [(61)Cu]Cu-ATSM and [(18)F]FMISO, were characterized via computational modeling to address these challenges...
  28. Yuan H, Schroeder T, Bowsher J, Hedlund L, Wong T, Dewhirst M. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med. 2006;47:989-98 pubmed
    ..The aim of this study was to evaluate (64)Cu-ATSM as a hypoxia PET marker by comparing autoradiographic distributions of (64)Cu-ATSM with a well-established hypoxia marker drug, EF5...
  29. Cai W, Chen K, He L, Cao Q, Koong A, Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging. 2007;34:850-8 pubmed
    ..Here we report for the first time the quantitative positron emission tomography (PET) imaging of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab...
  30. Garrison J, Rold T, Sieckman G, Figueroa S, Volkert W, Jurisson S, et al. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med. 2007;48:1327-37 pubmed
    ..The study directly compares 64Cu bombesin analogs using the CB-TE2A and DOTA chelation systems in a prostate cancer xenograft SCID (severely compromised immunodeficient) mouse model...
  31. Hansen A, Kristensen A, Jørgensen J, McEvoy F, Busk M, van der Kogel A, et al. (64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry. Radiat Oncol. 2012;7:89 pubmed publisher
  32. Rockey W, Huang L, Kloepping K, Baumhover N, Giangrande P, Schultz M. Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging. Bioorg Med Chem. 2011;19:4080-90 pubmed publisher
    ..In summary, key parameters were established for optimal radiolabeling of RNA aptamers for eventual PET imaging with (64)Cu...
  33. Paudyal B, Paudyal P, Oriuchi N, Hanaoka H, Tominaga H, Endo K. Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts. Cancer Sci. 2011;102:117-21 pubmed publisher
    ..6 ± 1.5 %ID/g) due to hepatic clearance of the tracer. The present study successfully showed (64) Cu-DOTA-bevacizumab as a potential PET tracer for non-invasive imaging of VEGF expression in colorectal cancer xenografts...
  34. Wu A, Yazaki P, Tsai S, Nguyen K, Anderson A, McCarthy D, et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci U S A. 2000;97:8495-500 pubmed
    ..Average target/background ratios relative to neighboring tissue were 3-4:1. Engineered antibody fragments labeled with positron-emitting isotopes such as copper-64 provide a new class of agents for PET imaging of tumors...
  35. Evans M, Smith Jones P, Wongvipat J, Navarro V, Kim S, Bander N, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A. 2011;108:9578-82 pubmed publisher
  36. Hansen A, Kristensen A, Law I, McEvoy F, Kjær A, Engelholm S. Multimodality functional imaging of spontaneous canine tumors using 64Cu-ATSM and 18FDG PET/CT and dynamic contrast enhanced perfusion CT. Radiother Oncol. 2012;102:424-8 pubmed publisher
    ..In addition (64)Cu-ATSM distribution over time was evaluated...
  37. Adonai N, Adonai N, Nguyen K, Walsh J, Iyer M, Toyokuni T, et al. Ex vivo cell labeling with 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography. Proc Natl Acad Sci U S A. 2002;99:3030-5 pubmed
    ..Given the longer t(1/2) of 64Cu (12.7 h) relative to 18F (110 min), longer cell-tracking periods (up to 24-36 h) should be possible now with PET...
  38. Ferdani R, Stigers D, Fiamengo A, Wei L, Li B, Golen J, et al. Synthesis, Cu(II) complexation, 64Cu-labeling and biological evaluation of cross-bridged cyclam chelators with phosphonate pendant arms. Dalton Trans. 2012;41:1938-50 pubmed publisher
    ..Both new compounds showed rapid clearance with similar or lower accumulation in non-target organs/tissues when compared to other copper chelators including CB-TE2A, NOTA and Diamsar...
  39. Matarrese M, Bedeschi P, Scardaoni R, Sudati F, Savi A, Pepe A, et al. Automated production of copper radioisotopes and preparation of high specific activity [(64)Cu]Cu-ATSM for PET studies. Appl Radiat Isot. 2010;68:5-13 pubmed publisher
    ..Preliminary production yields of (60)Cu and (64)Cu were 400 and 300mCi, respectively. (64)Cu was used to radiolabel the hypoxia detection tracer ATSM with a specific activity of 2.2+/-1.3Ci/micromol...
  40. Black N, McJames S, Rust T, Kadrmas D. Evaluation of rapid dual-tracer (62)Cu-PTSM + (62)Cu-ATSM PET in dogs with spontaneously occurring tumors. Phys Med Biol. 2008;53:217-32 pubmed publisher
    ..Rapid multi-tracer PET has the potential to improve tumor assessment for image-guide therapy and monitoring, and further investigation with these and other tracers is warranted...
  41. Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik D, Aikawa E, et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation. 2008;117:379-87 pubmed
  42. Niu G, Li Z, Cao Q, Chen X. Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab. Eur J Nucl Med Mol Imaging. 2009;36:1510-9 pubmed publisher
    ..In this study, we aimed to noninvasively monitor the HER-2 response to 17-DMAG treatment in xenografted mice...
  43. Skovgaard D, Kjaer M, Madsen J, Kjaer A. Noninvasive 64Cu-ATSM and PET/CT assessment of hypoxia in rat skeletal muscles and tendons during muscle contractions. J Nucl Med. 2009;50:950-8 pubmed publisher
  44. Dearling J, Voss S, Dunning P, Snay E, Fahey F, Smith S, et al. Imaging cancer using PET--the effect of the bifunctional chelator on the biodistribution of a (64)Cu-labeled antibody. Nucl Med Biol. 2011;38:29-38 pubmed publisher
    Use of copper radioisotopes in antibody radiolabeling is challenged by reported loss of the radionuclide from the bifunctional chelator used to label the protein...
  45. Sprague J, Peng Y, Sun X, Weisman G, Wong E, Achilefu S, et al. Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res. 2004;10:8674-82 pubmed
    ..6.2)hexadecane (CB-TE2A) compared with 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA)...
  46. Wadas T, Wong E, Weisman G, Anderson C. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev. 2010;110:2858-902 pubmed publisher
  47. Smith S. Molecular imaging with copper-64. J Inorg Biochem. 2004;98:1874-901 pubmed
  48. Dehdashti F, Grigsby P, Mintun M, Lewis J, Siegel B, Welch M. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys. 2003;55:1233-8 pubmed
    ..We have investigated whether pretreatment tumor hypoxia assessed by positron emission tomography (PET) with Cu-60 diacetyl-bis(N(4)-methylthiosemicarbazone) ((60)Cu-ATSM) predicts responsiveness to subsequent therapy in cervical cancer...
  49. Boswell C, Sun X, Niu W, Weisman G, Wong E, Rheingold A, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem. 2004;47:1465-74 pubmed
    The increased use of copper radioisotopes in radiopharmaceutical applications has created a need for bifunctional chelators (BFCs) that form stable radiocopper complexes and allow covalent attachment to biological molecules...
  50. Fani M, Del Pozzo L, Abiraj K, Mansi R, Tamma M, Cescato R, et al. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference. J Nucl Med. 2011;52:1110-8 pubmed publisher
    ..Factors determining the performance of radioantagonists have only scarcely been studied. Here, we report on the development and evaluation of four (64)Cu or (68)Ga radioantagonists for PET of sst2-positive tumors...
  51. Lewis J, Sharp T, Laforest R, Fujibayashi Y, Welch M. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med. 2001;42:655-61 pubmed
    ..This study was undertaken to confirm the pO2 dependence of this selective uptake in vivo by correlating Cu-ATSM uptake with measured tumor pO2...
  52. Dumont R, Deininger F, Haubner R, Maecke H, Weber W, Fani M. Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of ?(?)?(3) integrin expression and facile radiosynthesis. J Nucl Med. 2011;52:1276-84 pubmed publisher
    ..The development of (68)Ga-RGD peptides would be of great utility given the convenience of (68)Ga production and radiolabeling, and (64)Cu-RGD peptides allow for delayed imaging with potentially improved tumor-to-background ratios...
  53. Wipke B, Wang Z, Kim J, McCarthy T, Allen P. Dynamic visualization of a joint-specific autoimmune response through positron emission tomography. Nat Immunol. 2002;3:366-72 pubmed
    ..The rapid kinetics of anti-GPI IgG joint localization supports a model in which autoantibodies bind directly to pre-existing extracellular GPI in normal healthy mouse joints...
  54. Cai W, Wu Y, Chen K, Cao Q, Tice D, Chen X. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res. 2006;66:9673-81 pubmed
    ..Chemotherapeutics or radiotherapeutics using Abegrin as the delivering vehicle may also be effective in treating integrin alpha(v)beta(3)-positive tumors...
  55. Sprague J, Peng Y, Fiamengo A, Woodin K, Southwick E, Weisman G, et al. Synthesis, characterization and in vivo studies of Cu(II)-64-labeled cross-bridged tetraazamacrocycle-amide complexes as models of peptide conjugate imaging agents. J Med Chem. 2007;50:2527-35 pubmed
    ..Clearance of 64Cu-cross-bridged monoamides from nontarget organs suggests good in vivo stability, thus supporting the use of CB-TE2A as a bifunctional chelator without modifications to the macrocycle backbone...
  56. Yoshii Y, Furukawa T, Kiyono Y, Watanabe R, Mori T, Yoshii H, et al. Internal radiotherapy with copper-64-diacetyl-bis (N4-methylthiosemicarbazone) reduces CD133+ highly tumorigenic cells and metastatic ability of mouse colon carcinoma. Nucl Med Biol. 2011;38:151-7 pubmed publisher
    ..In this study, we evaluated the therapeutic effect of (64)Cu-ATSM in relation to CD133 expression using this model...
  57. Lee H, Li Z, Chen K, Hsu A, Xu C, Xie J, et al. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med. 2008;49:1371-9 pubmed publisher
    ..The purpose of this study was to develop a bifunctional iron oxide (IO) nanoparticle probe for PET and MRI scans of tumor integrin alphavbeta3 expression...